Philip Gotwals Increases Stake in OmniAb, Inc. with Recent Purchase

Philip Gotwals bought 20,000 shares of OmniAb, Inc. on June 17, 2026.

Written by EarningsIQ · Published Jun 19, 2026, 3:01 AM EDT · Updated Jun 20, 2026, 7:00 AM EDT

Key Points

Philip Gotwals purchased 20,000 shares of OmniAb, Inc. on June 17, 2026, with no disclosed transaction value.
OmniAb, Inc. trades on NasdaqGM at around $2.34, with a market cap of $339 million and a 52-week range of $1.30 to $2.79.
RBC Capital and HC Wainwright & Co. both maintain 'buy' ratings on OmniAb, with price targets of $3.00 and $11.00 respectively.

Philip Gotwals recently bought 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI) on June 17, 2026. The purchase did not have a disclosed transaction value. OmniAb, a biotechnology company, specializes in licensing discovery research technology to pharmaceutical and biotech firms worldwide.

Insider Buying and Selling at OmniAb, Inc.

On June 17, 2026, OmniAb, Inc. saw several insider transactions. Philip Gotwals added 20,000 shares to his holdings. Other notable transactions on the same date included Jennifer Cochran buying 40,000 shares and selling 20,000 shares, while Carolyn Bertozzi acquired 40,000 shares and sold 20,000 shares. John Higgins also purchased 20,000 shares. None of these transactions were under a pre-planned trading program.

Other Institutional Activity in OmniAb, Inc.

BlackRock, Inc. increased its position in OmniAb by 41,900 shares, bringing its total to over 8.1 million shares valued at about $12.7 million. Geode Capital Management, LLC also boosted its holdings by 202,887 shares, ending with nearly 2.9 million shares worth approximately $4.6 million. Conversely, Cadian Capital Management, LP reduced its stake by 277,825 shares, totaling over 4.1 million shares valued at about $6.5 million.

OmniAb, Inc. Stock Snapshot

Shares of OmniAb, Inc. are trading around $2.34. The company has a market cap of approximately $339 million. The stock's 52-week range is between $1.30 and $2.79, with a 50-day moving average of $1.97 and a 200-day moving average of $1.80. OmniAb, Inc. shows a strong liquidity position with a current ratio of 4.80 and a quick ratio of 4.55, though it carries a debt-to-equity ratio of 7.49.

Analysts Set New Price Targets

Analysts remain optimistic about OmniAb, Inc.'s prospects. RBC Capital maintained its 'buy' rating with a price target of $3.00 as of August 7, 2025. HC Wainwright & Co. reiterated their 'buy' rating with a higher target of $11.00 on March 19, 2025. The consensus target price among analysts is about $7.33, with six analysts providing opinions.

About OmniAb, Inc.

OmniAb, Inc., headquartered in Emeryville, California, operates in the biotechnology sector. The company offers discovery research technology to pharmaceutical and biotech companies, facilitating the development of therapeutics. OmniAb's platform uses advanced biological intelligence to create and screen diverse antibody repertoires, aiding in drug development. Founded in 2012, the company employs 89 people under the leadership of CEO Matthew W. Foehr.

Bottom Line

Philip Gotwals' recent purchase of OmniAb shares highlights ongoing interest in the company's potential. Investors often track insider buying as it may signal confidence in the company's future. However, it's important to remember that such transactions are disclosed after they occur and may not reflect current holdings or future intentions.